Saturday, November 21, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Earnings

Regulatory Pressure Mounts for Telehealth Firm Hims & Hers

Robert Sasse by Robert Sasse
September 24, 2025
in Earnings, Healthcare, Nasdaq, Pharma & Biotech
0
Hims & Hers Stock
0
SHARES
160
VIEWS
Share on FacebookShare on Twitter

The telehealth company Hims & Hers finds itself navigating a significant regulatory challenge following action by the U.S. Food and Drug Administration (FDA). This development casts a shadow over the firm’s otherwise impressive growth trajectory, raising questions about the impact on its future performance.

Strong Quarterly Performance Amidst Headwinds

Despite the emerging regulatory concerns, the company’s operational results for the second quarter of 2025 were exceptionally strong. The financial and subscriber metrics underscore its rapid expansion:

  • Revenue reached $544.8 million, representing a substantial 73% year-over-year increase.
  • The subscriber base grew to over 2.4 million, a 31% jump compared to the previous year.
  • Net income was reported at $42.5 million.
  • Management has reaffirmed its full-year revenue guidance of between $2.3 and $2.4 billion.

FDA Warning Letter Targets Marketing Practices

The situation escalated on September 9th when the FDA issued a formal warning letter to the company. The communication centered on the marketing of compounded semaglutide products, which are a key offering in Hims & Hers’s lucrative weight-loss segment. The agency alleged that statements on the company’s website were “false or misleading.”

A primary point of contention is the alleged portrayal of non-FDA-approved, compounded medications as being equivalent to their approved counterparts. News of the warning became public on September 16th, triggering an immediate and sharp decline in the company’s share price. Hims & Hers now has a 15-working-day deadline to outline corrective actions to the regulator.

Should investors sell immediately? Or is it worth buying Hims & Hers?

Insider Trading Activity Adds to Investor Anxiety

Compounding the regulatory pressure, recent transactions by company executives have drawn investor scrutiny. Chief Financial Officer Oluyemi Okupe sold 145,000 shares on September 15th. Furthermore, a separate filing on September 22nd revealed that another insider plans to divest nearly 155,000 shares. The timing of these sales, coinciding with the regulatory turbulence, has contributed to market unease.

Wall Street’s Cautious Stance

The investment community appears divided in its assessment. While some firms, such as Canaccord Genuity, maintain a bullish outlook with a price target of $68, a more cautious tone prevails across the broader analyst spectrum. The consensus rating has shifted noticeably, with most experts now advising a “Hold” position—a significant change from the previously dominant “Buy” recommendations.

The critical uncertainty for investors is whether the company’s robust growth can outweigh the potential financial and reputational damage from the FDA’s intervention.

Ad

Hims & Hers Stock: Buy or Sell?! New Hims & Hers Analysis from November 21 delivers the answer:

The latest Hims & Hers figures speak for themselves: Urgent action needed for Hims & Hers investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 21.

Hims & Hers: Buy or sell? Read more here...

Tags: Hims & Hers
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Micron Technology Stock
AI & Quantum Computing

Micron’s Rally Faces Its Moment of Reckoning: A Downgrade, a Labor Standoff, and a Date With the Numbers

September 9, 2026
Nvidia Stock
AI & Quantum Computing

Nvidia’s Insider Sales and $12.9 Billion Acquisition Paint a Portrait of a Company in Overdrive

September 7, 2026
Novo Nordisk Stock
Analysis

Novo Nordisk Faces a New Front: 300-Fold Rise in GLP-1 Scripts for Children Under 12

September 7, 2026
Next Post
Palantir Stock

Palantir Shares Surge on Major Boeing Partnership and Analyst Upgrade

Twilio Stock

Twilio's Crossroads: AI Growth Confronts Profitability Concerns

Synopsys Stock

Synopsys Shares Plummet Following Disastrous Quarterly Report

Recommended

WM stock news

Spire Wealth Management Shows Confidence in Churchill Downs Incorporated with New Acquisition and Bet on Future Growth

3 years ago
Chevron Stock

Chevron Shares Surge Amid Global Oil Supply Disruption

8 months ago
Q2 Holdings Stock

Inclusion in S&P SmallCap 600 Index Ignites Q2 Holdings Stock Rally

1 year ago
REV Stock

REV Group Shares Hit Record High Amid Political Scrutiny

1 year ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum DroneShield Eli Lilly FALLBACK Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Netflix Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power Robinhood Rocket Lab USA Salesforce Strategy Take-Two Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics XRP
No Result
View All Result

Highlights

Nvidia Posts a Record Quarter, but Rate-Hike Fears Still Set the Tone

Home Depot Beats, Shares Slip: Bigger Tickets, Fewer Customers

Rotation, Not Panic: Retailers Test Where Tech’s Money Went

At 5.15%, the 10-Year Treasury Picks the Winners

Bitcoin Slips Below $70,000, and a Samsung Rumor Lifts Modine

Huang Exits, Cisco Reports: Who Actually Gets Paid for AI

Trending

CrowdStrike Stock
Newsletter

93% of Stocks Fall as CrowdStrike Courts Zscaler

by Stephanie Dugan
November 21, 2026
0

Dear readers, The question heading into Friday was whether Anthropic would hold its $83 offer price. It...

Nvidia Stock

Anthropic Lists at a Premium, but the Sell-Off Keeps Going

November 20, 2026
Bitcoin Stock

Anthropic’s $81 Billion IPO Meets a Market in Need of Good News

November 19, 2026
Nvidia Stock

Nvidia Posts a Record Quarter, but Rate-Hike Fears Still Set the Tone

November 18, 2026
Home Depot Stock

Home Depot Beats, Shares Slip: Bigger Tickets, Fewer Customers

November 17, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • 93% of Stocks Fall as CrowdStrike Courts Zscaler
  • Anthropic Lists at a Premium, but the Sell-Off Keeps Going
  • Anthropic’s $81 Billion IPO Meets a Market in Need of Good News

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com